Jaguar Health vs Trinity Biotech
JAGX and TRIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAGX and TRIB compare
Jaguar Health grew revenue faster over the last twelve months (136% versus −28.9% for Trinity Biotech).
Jaguar Health scores higher on the StockData Score (3 against 1 for Trinity Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAGX | TRIB |
|---|---|---|
| Size and price | ||
| Market cap | $2.1M | – |
| Share price | $0.400 | $6.10 |
| Change, 1 year | −100.0% | −77.4% |
| Change, 5 years | −100% | −97.9% |
| Beta (5Y) | 2.17 | 1.44 |
| Employees | 47 | 287 |
| StockData Score | ||
| Total score | 3 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 0 |
| Health score | 0 | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.1× | – |
| Growth | ||
| Revenue growth (TTM) | 136% (better) | −28.9% |
| Revenue growth, 5Y average | 4.2% (better) | −15.6% |
| Profitability | ||
| Gross margin | 82.3% (better) | 38.6% |
| Operating margin | −93.1% | −36.1% (better) |
| Net margin | – | −85.4% |
| FCF margin | – | −13.7% |
| Financial health | ||
| Interest coverage | −25.9× | −0.7× (better) |
| Current ratio | 0.69 (better) | 0.25 |
| Altman Z-score | −18.45 | – |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | – | 0.01% |
| Held by insiders | 17.1% | 51.7% |
| Short interest, % of float | 4.7% | – |
Go deeper
- JAGX stock overview
- JAGX income statement
- JAGX valuation and score
- TRIB stock overview
- TRIB income statement
- TRIB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.